The influence of amifostine administration prior to cyclophosphamide on in vitro maturation of mouse oocytes

  • Afsaneh Golkar-Narenji
  • Zeinab Barekati
  • Hussein Eimani
  • Fatemeh Shabani
  • Hamid Gourabi
Gamete Biology



The protective effect of amifostine against cyclophosphamide (CP) was evaluated on mouse oocytes.

Materials and methods

Female mice were divided into four groups as follows: group1: cyclophosphamide (CP) (75 mg/kg, i.p) injection, group2: amifostine (250 mg/kg, i.p) injection, group3: amifostine (250 mg/kg, i.p) administered prior to CP (75 mg/kg, i.p) injection, Control group with injection of saline. About 21 days after injection, in vitro maturation (IVM) of oocytes was recorded. Furthermore the percentage of aneuploid oocytes was determined.


In the CP group IVM rate was significantly decreased and aneploidy rate was significantly increased when compared to other groups (p < 0.05). With the administration of Amifostine prior to CP injection IVM rate was increased and aneploidy rate was decreased.


Depletion in IVM rate with administration of CP is due its adverse effects on oocyte quality. Amifostine administration prior to CP injection appears to modulate deleterious effects of CP on oocytes.


Amifostine Aneuploidy Chromosome Cyclophosphamide Maturation Oocyte 



This research supported by Royan Institute.


  1. 1.
    Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332(14):901–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Pryor JL, Hughes C, Foster W, Hales BF, Robaire B. Critical windows of exposure for children’s health: the reproductive system in animals and humans. Environ Health Perspect. 2000;108 Suppl 3:491–503.PubMedGoogle Scholar
  3. 3.
    Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther. 1988;37(3):301–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Becker K, Schoneich J. Expression of genetic damage induced by alkylating agents in germ cells of female mice. Mutat Res. 1982;92(1–2):447–64.PubMedGoogle Scholar
  5. 5.
    Byrne J, Mulvihill JJ, Myers MH, Connelly RR, Naughton MD, Krauss MR, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med. 1987;317(21):1315–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964–1988 in Ontario, Canada. Am J Epidemiol. 1999;150(3):245–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Pydyn EF, Ataya KM. Effect of cyclophosphamide on mouse oocyte in vitro fertilization and cleavage: recovery. Reprod Toxicol. 1991;5(1):73–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39(4):1403–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Phillips TL. Sensitizers and protectors in clinical oncology. Semin Oncol. 1981;8(1):65–82.PubMedGoogle Scholar
  10. 10.
    Wills BK, Haller NA, Peter D, White LJ. Use of amifostine, a novel cytoprotective, in alpha-amanitin poisoning. Clin Toxicol (Phila). 2005;43(4):261–7.Google Scholar
  11. 11.
    Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs. 2002;13(3):181–209.PubMedCrossRefGoogle Scholar
  12. 12.
    Savoye C, Swenberg C, Hugot S, Sy D, Sabattier R, Charlier M, et al. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int J Radiat Biol. 1997;71(2):193–202.PubMedCrossRefGoogle Scholar
  13. 13.
    Weiss JF. Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ Health Perspect. 1997;105 Suppl 6:1473–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Vendramini V, Sasso-Cerri E, Miraglia SM. Amifostine reduces the seminiferous epithelium damage in doxorubicin-treated prepubertal rats without improving the fertility status. Reprod Biol Endocrinol. 2010;8:3.PubMedCrossRefGoogle Scholar
  15. 15.
    Barekati Z, Golkar-Narenji A, Totonchi M, Radpour R, Gourabi H. Effects of amifostine in combination with cyclophosphamide on female reproductive system. Reprod Sci. 2012;19(5):539–46.PubMedCrossRefGoogle Scholar
  16. 16.
    Handel MA, Sun F. Regulation of meiotic cell divisions and determination of gamete quality: impact of reproductive toxins. Semin Reprod Med. 2005;23(3):213–21.PubMedCrossRefGoogle Scholar
  17. 17.
    Kenney LB, Laufer MR, Grant FD, Grier H, Diller L. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001;91(3):613–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Colvin OM. An overview of cyclophosphamide development and clinical applications. Curr Pharm Des. 1999;5(8):555–60.PubMedGoogle Scholar
  19. 19.
    Hansmann I. Chromosome aberrations in metaphase II-oocytes. Stage sensitivity in the mouse oogenesis to amethopterin and cyclophosphamide. Mutat Res. 1974;22(2):175–91.PubMedCrossRefGoogle Scholar
  20. 20.
    Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol. 1999;33(1):29–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009;360(9):902–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Meirow D, Levron J, Eldar-Geva T, Hardan I, Fridman E, Zalel Y, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005;353(3):318–21.PubMedCrossRefGoogle Scholar
  24. 24.
    Vesta C, Uthrakumar R, Jerome Das S, Varghese B. Poly[tetra-aqua-bis(mu(2)-2,4,6-trinitro-phenolato)barium(II)]. Acta Crystallogr Sect E Struct Rep Online. 2008;64(Pt 3):m451–2.PubMedCrossRefGoogle Scholar
  25. 25.
    Chian RC, Huang JY, Gilbert L, Son WY, Holzer H, Cui SJ, et al. Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. Fertil Steril. 2009;91(6):2391–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Roberts CG, O’Neill C. A simplified method for fixation of human and mouse preimplantation embryos which facilitates G-banding and karyotypic analysis. Hum Reprod. 1988;3(8):990–2.PubMedGoogle Scholar
  27. 27.
    Ataya KM, Valeriote FA, Ramahi-Ataya AJ. Effect of cyclophosphamide on the immature rat ovary. Cancer Res. 1989;49(7):1660–4.PubMedGoogle Scholar
  28. 28.
    Keel AB, Verner Mey J, De Jonge JC. Handbook of the assisted reproduction laboratory. London: CRC Press LLC; 2000.Google Scholar
  29. 29.
    Jancar N, Kopitar AN, Ihan A, Virant Klun I, Bokal EV. Effect of apoptosis and reactive oxygen species production in human granulosa cells on oocyte fertilization and blastocyst development. J Assist Reprod Genet. 2007;24(2–3):91–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Sorensen RA, Wassarman PM. Relationship between growth and meiotic maturation of the mouse oocyte. Dev Biol. 1976;50(2):531–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Sun XF, Zhang WH, Chen XJ, Xiao GH, Mai WY, Wang WH. Spindle dynamics in living mouse oocytes during meiotic maturation, ageing, cooling and overheating: a study by polarized light microscopy. Zygote. 2004;12(3):241–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Rohrborn G, Kuhn O, Hansmann I, Thon K. Induced chromosome aberrations in early embryogenesis of mice. Humangenetik. 1971;11(4):316–22.PubMedCrossRefGoogle Scholar
  33. 33.
    Rohrborn G, Hansmann I. Induced chromosome aberrations in unfertilized oocytes of mice. Humangenetik. 1971;13(3):184–98.PubMedCrossRefGoogle Scholar
  34. 34.
    Barekati Z, Gourabi H, Valojerdi MR, Yazdi PE. Previous maternal chemotherapy by cyclophosphamide (Cp) causes numerical chromosome abnormalities in preimplantation mouse embryos. Reprod Toxicol. 2008;26(3–4):278–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Kuechler A, Dreidax M, Pigorsch SU, Liehr T, Claussen U, Wendt TG, et al. Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH. Strahlenther Onkol. 2003;179(7):493–8.PubMedGoogle Scholar
  36. 36.
    Xuncla M, Barquinero JF, Caballin MR, Craven-Bartle J, Ribas M, de Vega JM, et al. Cytogenetic damage induced by radiotherapy. Evaluation of protection by amifostine and analysis of chromosome aberrations persistence. Int J Radiat Biol. 2008;84(3):243–51.PubMedCrossRefGoogle Scholar
  37. 37.
    Camelo RM, Kehdy FS, Salas CE, Lopes MT. Amifostine protection against mitomycin-induced chromosomal breakage in fanconi anaemia lymphocytes. Molecules. 2008;13(8):1759–72.PubMedCrossRefGoogle Scholar
  38. 38.
    Kim SS, Donnez J, Barri P, Pellicer A, Patrizio P, Rosenwaks Z, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012;29(6):465–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci. 2001;943:296–315.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Afsaneh Golkar-Narenji
    • 1
  • Zeinab Barekati
    • 2
  • Hussein Eimani
    • 3
  • Fatemeh Shabani
    • 4
  • Hamid Gourabi
    • 1
  1. 1.Department of Genetics at Reproductive Biomedicine Research CenterRoyan Institute for Reproductive Biomedicine, ACECRTehranIran
  2. 2.Laboratory for Gynecological Oncology, Women’s Hospital/Department of BiomedicineUniversity of BaselBaselSwitzerland
  3. 3.Department of Embryology at Reproductive Biomedicine Research CenterRoyan Institute for Reproductive Biomedicine, ACECRTehranIran
  4. 4.Department of Epidemology and Reproductive Health at Reproductive Epidemiology Research CenterRoyan Institute For Reproductive Biomedicine, ACECRTehranIran

Personalised recommendations